The inoculum in this B-ALL xenograft model was a mixture of 1% CD19− or CD22− B-ALL with 99% wild-type cells (CD19+/CD22+), which mimics relapse from a small pre-existent clone as observed in clinical trials. Here, CD19 is linked to acute lymphoblastic leukemia.